DCLK1 and neoplasm: Tumor-bearing mice were given intravenous (i.v.) injections of DCLK1 CAR-T or mock CAR-T cells (1 × 107 cells/mice/dose) every week for three weeks (days 7, 14, and 21 post-cell implantations; Figure 5A).